In the late 1980s, cardiologists thought they had cracked the code. They knew that patients who developed irregular heartbeats, premature ventricular contractions (PVCs), after a heart attack were more likely to die. They had drugs, encainide and flecainide, that reliably suppressed those irregular beats. The intuition was flawless: Suppress the
What oncology learned the hard way—and tech keeps relearning. Why Tech Should Pay Attention to Cancer Trials Most product teams think of A/B testing as a modern invention: lean, data‑driven, and efficient. But step back far enough and today’s experimentation culture in tech looks eerily like
In 2014, during a major snowstorm, Uber ran a randomized test by turning off surge pricing for a subset of riders. Some waited longer. Others never got a ride at all. It wasn’t just a pricing tweak. It was a trial of behavior, supply, and equity. Trials, once reserved
